Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

RARE PHOTOS: Hims hers org | Vintage Vibes

As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner

Hims & Hers Health shares have surged 45% in 30 days on GLP-1 coverage shifts, but overbought technicals, a Hold rating, and rising short interest suggest a pullback may be near.

MarketBeat

FDA to discuss easing restrictions on peptides despite safety concerns

Committee will meet in July to discuss peptides now sold in gray market despite limited evidence of safety and efficacy

The Guardian - US

Hims & Hers Eyes Global Growth: Will $1.15B Eucalyptus Deal Fuel Its Recovery or Dilute Shareholders?

Hims & Hers is acquiring Australian telehealth platform Eucalyptus as part of its international expansion plan while using $350 million in convertible senior notes.

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

The Silver Lining of Last Week's Hims & Hers Earnings Miss

Hims & Hers plunged 23% after a major Q1 earnings miss, but long-term growth stays intact via its Novo Nordisk GLP-1 partnership and a late 2026 expansion.

MarketBeat

Hims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?

Hims & Hers Health posted a Q1 FY2026 double miss, with an EPS loss of $0.40 and revenue of $608.1 million, sending shares down more than 12% after hours.

MarketBeat

Hims & Hers Health Q1 Earnings Call Highlights

Hims & Hers Health (NYSE:HIMS) reported first-quarter 2026 revenue growth and raised its full-year revenue outlook, while executives said a strategic shift in the company’s weight-loss business is creating short-term margin pressure and volatility in GAAP results. On the company’s earnings call

MarketBeat

Hims earnings today: Why Hims & Hers Health stock dropped despite raising revenue forecast - here's what investors need to know

Hims stock after Hims & Hers earnings: Hims & Hers Health shares dropped significantly after reporting a surprise first-quarter loss and revenue below expectations. Despite these weak results, the company raised its full-year revenue outlook and projected strong second-quarter revenue, as it navigates regulatory scrutiny around weight-loss drugs.

The Economic Times

Read news from The Economist, FT, and more,
with one subscription

Should You Buy HIMS Stock Following Friday's Rally?

Hims & Hers stock rallied on Friday on a major regulatory update and bullish analyst note. Here’s how high HIMS shares could realistically fly through the end of 2026.

Barchart

Hims & Hers Stock Surges 13% on FDA Peptide Review Optimism and Telehealth Momentum

Shares of Hims & Hers Health Inc. climbed sharply in morning trading Friday as investors bet that potential regulatory relief on compounded peptides could strengthen the telehealth company's weight-loss offerings and broader platform growth.

International Business Times

RFK Jr. Just Gave Hims & Hers Stock a Jolt. Should You Chase the Rally Here?

Hims & Hers stock rallies as RFK Jr. says FDA may remove restrictions on certain peptides. But HIMS shares remain unattractive to own in 2026.

Barchart

Hims and Hers reveal cyberattack — customer support system hacked and personal info stolen, here's what we know

At least 500 people were affected in breach at Hims and Hers.

TechRadar

Novo Nordisk Just Announced Wegovy Subscriptions. Does That Make NVO Stock a Buy?

Wegovy subscriptions may create interest, but there is a major threat looming for Novo Nordisk.

Barchart

Should You Chase the Rally in Hims & Hers Stock Today?

Hims & Hers shares extend gains as Eli Lilly warns impurity it discovered in compounded versions of its weight-loss drug has health implications. Here’s why HIMS stock isn’t worth owning here.

Barchart

Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal

Hims & Hers shares surged 46% after partnering with Novo Nordisk to offer FDA-approved Ozempic and Wegovy, moving away from compounded GLP-1 alternatives.

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

International Business Times

Novo Nordisk and Hims & Hers Turn Patent Dispute Into Business Opportunity

Novo Nordisk drops its lawsuit against Hims & Hers as the companies partner to offer FDA-approved Wegovy and Ozempic through the telehealth platform.

Barchart

Hims & Hers Stock Is Challenging Its 50-Day Moving Average. Should You Bet on a Turnaround Here?

Hims & Hers shares soared as Novo Nordisk dropped its GLP-1 lawsuit. But there’s reason to still sell HIMS stock today. Find out more!

The Independent UK

Novo Nordisk drops lawsuit over weight loss medications, enters collaboration with online pharmacy

The news sent shares of Hims & Hers Health Inc. soaring by more than 40% in Monday morning trading

MarketBeat

Hims & Hers in Free Fall: Why Analysts See Nearly 150% Upside

HIMS is down 48% in the past month following a Novo Nordisk lawsuit. But, analysts expect record revenue when the company reports earnings this month.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

As Hims & Hers Gets Hit With Major Wegovy Loss, Should You Buy the Dip in Deeply Oversold HIMS Stock?

Hims & Hers shares crater as Novo Nordisk files a lawsuit against the telehealth firm. BofA analysts see significant further downside in HIMS stock.

The Independent UK

Super Bowl ads try to overcome tough times with health, caring and the usual laughs

At a difficult time for America, Super Bowl advertisers are asking viewers to take care of themselves and others — and maybe even crack a smile

Euronews

US health company launches weight-loss pill that Novo Nordisk calls an 'untested knockoff'

The American telehealth company announced the launch of a compounded weight-loss pill for €41, drawing criticism from Novo Nordisk, the Danish company behind the weight-loss drug Wegovy, which called the product an “untested knockoff.”

Fortune

Hims and Hers Super Bowl ad highlights 'uncomfortable truth' about elite healthcare for the rich and 'broken' system for the rest

The company is putting wealth inequality center stage as millions are expected to drop their Obamacare plans.

Benzinga

What's Going On With Shares Of Hims & Hers Health Thursday?

Shares of Hims Hers Health, Inc. (NASDAQ:HIMS) are trending Thursday morning. The San Francisco-based telehealth company announced an international expansion.

Benzinga

Hims & Hers Introduces Labs With Annual Plans For Comprehensive Testing

Hims Hers Health, Inc. (NYSE:HIMS) announced the launch of Labs, a new way for customers to understand their overall health and identify ways to improve and maintain it.

MarketBeat

Why Hims & Hers Stock May Be a Buy After Mixed Q3 Results

Hims & Hers Health delivered a mixed earnings report and announced a potential Wegovy partnership with Novo Nordisk; the downside risk to HIMS stock looks low.

1 2 3 4

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Wall Street Journal

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.